CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Current Assets:
Cash and cash equivalents	$ 13,979	$ 14,546
Marketable debt securities	2,987	1,285
Receivables	9,369	8,501
Inventories	2,095	2,074
Other current assets	4,832	3,786
Total Current Assets	33,262	30,192
Property, plant and equipment	6,049	5,886
Goodwill	20,502	20,547
Other intangible assets	42,527	53,243
Deferred income taxes	1,439	1,161
Marketable debt securities	0	433
Other non-current assets	5,535	7,019
Total Assets	109,314	118,481
Current Liabilities:
Short-term debt obligations	4,948	2,340
Accounts payable	2,949	2,713
Other current liabilities	13,971	14,027
Total Current Liabilities	21,868	19,080
Deferred income taxes	4,501	5,407
Long-term debt	39,605	48,336
Other non-current liabilities	7,334	7,776
Total Liabilities	73,308	80,599
Commitments and contingencies
Bristol-Myers Squibb Company Shareholders’ Equity:
Preferred stock, $2 convertible series, par value $1 per share: Authorized 10 million shares; issued and outstanding 3,484 in 2021 and 3,484 in 2020, liquidation value of $50 per share	0	0
Common stock, par value of $0.10 per share: Authorized 4.5 billion shares; 2.9 billion issued in 2021 and 2020	292	292
Capital in excess of par value of stock	44,361	44,325
Accumulated other comprehensive loss	(1,268)	(1,839)
Retained earnings	23,820	21,281
Less cost of treasury stock — 747 million common shares in 2021 and 679 million common shares in 2020	(31,259)	(26,237)
Total Bristol-Myers Squibb Company Shareholders’ Equity	35,946	37,822
Noncontrolling interest	60	60
Total Equity	36,006	37,882
Total Liabilities and Equity	$ 109,314	$ 118,481